Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study

How I treat mucormycosis

(2011) D. P. Kontoyiannis et al.   BLOOD

Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007

(2011) A. Skiada et al.   CLINICAL MICROBIOLOGY AND INFECTION

Effect of pH and Comedication on Gastrointestinal Absorption of Posaconazole

(2011) Jeroen Walravens et al.   CLINICAL PHARMACOKINETICS

Lack of Evidence for Exposure–Response Relationship in the Use of Posaconazole as Prophylaxis Against Invasive Fungal Infections

(2011) O A Cornely et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Airborne fungus exposure prior to hospitalisation as risk factor for mould infections in immunocompromised patients

(2011) Gerhard Blum et al.   MYCOSES

Optimising absorption of posaconazole

(2011) Myke R. Green et al.   MYCOSES

Therapeutic Drug Monitoring of Voriconazole and Posaconazole

(2011) Trana Hussaini et al.   PHARMACOTHERAPY

Invasive fungal disease in patients treated for newly diagnosed acute leukemia

(2010) Sarah P. Hammond et al.   AMERICAN JOURNAL OF HEMATOLOGY

Recent Exposure to Caspofungin or Fluconazole Influences the Epidemiology of Candidemia: a Prospective Multicenter Study Involving 2,441 Patients

(2010) Olivier Lortholary et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

CandidaBloodstream Infections: Comparison of Species Distributions and Antifungal Resistance Patterns in Community-Onset and Nosocomial Isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009

(2010) Michael A. Pfaller et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation

(2010) J. R. Wingard et al.   BLOOD

Exposure–Response of Posaconazole Used for Prophylaxis Against Invasive Fungal Infections: Evaluating the Need to Adjust Doses Based on Drug Concentrations in Plasma

(2010) S H Jang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients

(2010) S. Perkhofer et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Posaconazole Therapeutic Drug Monitoring: a Reference Laboratory Experience

(2009) G. R. Thompson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Evaluation of the Abbott Real-Time HIV-1 quantitative assay with dried blood spot specimens

(2009) A. Marconi et al.   CLINICAL MICROBIOLOGY AND INFECTION

Activities of Antifungal Agents against Yeasts and Filamentous Fungi: Assessment according to the Methodology of the European Committee on Antimicrobial Susceptibility Testing

(2008) C. Lass-Florl et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Effect of Gastric Acid on the Absorption of Posaconazole

(2008) Rupali Jain et al.   CLINICAL INFECTIOUS DISEASES

Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

(2008) Ben De Pauw et al.   CLINICAL INFECTIOUS DISEASES

Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies

(2008) Jutta Auberger et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY